Search

Purpose: Potential treatments using autologous thrombocyte growth factors are an important reason to improve methods for isolating platelet-rich plasma (PRP). Two methods for extracting PRP directly by the surgeon are currently available; this study was conducted to compare the growth factor levels in the resulting PRP. Materials and Methods: Whole blood was drawn from 46 healthy donors (17 men, 29 women) aged 20 to 59 years (29.9 ± 7.8). PRP was then separated from each sample by both the PCCS (3i) and Curasan (PRP Kit, Curasan) methods. Results: The growth factor content differed significantly for TGF-β1 (PCCS 467.1 ng/mL; Curasan 79.7 ng/mL) (sign test P < .0001) and PDGF-AB (PCCS 251.8 ng/mL; Curasan 314.1 ng/mL) (P < .0001); this was less significant for IGF-I (PCCS 91.0 ng/mL; Curasan 69.5 ng/mL) (P < .02). The higher platelet count in the PCCS PRP (PCCS 2,232,500/μL; Curasan 1,140,500/μL) seemed to correlate with a higher level of TGF-β1 (Spearman's correlation coefficient, rS = 0.7), whereas the higher leukocyte count in the Curasan PRP (PCCS 15,300/μL; Curasan 33,150/μL) had only a minor correlation with higher levels of PDGF-AB (rS = 0.46). Discussion: The PCCS end product has both a higher platelet count and a higher total content of the growth factors investigated. Nevertheless, the biologic effect of the evaluated growth factor levels remains unknown. The amount of PRP necessary to achieve the intended biologic effects still remains unclear. Conclusion: PRP contains growth factors in high concentrations. Precise predictions of growth factor levels based on the thrombocyte counts of whole blood or PRP appeared limited. There are different sources for growth fators (platelets, leukocytes, plasma). [ABSTRACT FROM AUTHOR]

An important reason to improve methods for isolating platelet-rich plasma (PRP) is the potential use of autogenous platelet growth factors. In addition to the Curasan PRP kit (Curasan, Kleinostheim, Germany) and the platelet concentrated collection system (PCCSTM ) system, two new methods for the preparation of PRP by the surgeon are now available. This study compared the suitability of these new methods for the preparation of PRP. Whole blood was drawn from 54 healthy donors (33 men and 21 women) aged 23–79 years (38.0 ± 17.7 years). PRP was prepared from each donor's blood using both the Smart PRePTM system (Harvest Technologies Corporation, Munich, Germany) and the Friadent-Schütze method (PRP kit; Friadent-Schütze, Vienna, Austria). The platelet count in donor whole blood was 276 810 ± 59 440 /μl. Platelet counts differed significantly between the Smart PRP preparation (1227 890 ± 312 440 platelets/μl) and the Friadent-Schütze PRP preparation (1440 500 ± 501 700 platelets/μl) (sign test, P < 0.001). The Smart PRePTM system had a significantly higher collection efficiency (63.4 ± 7.9%) than the Friadent-Schütze kit (49.6 ± 13.6%) (sign test, P < 0.001). The leukocyte contents in the two platelet concentrates were similar (Smart PRePTM , 19 261 ± 8082 platelets/μl; Friadent-Schütze, 21 691 ± 16 430). Transforming growth factor (TGF)-β1 and platelet-derived growth factor (PDGF)-AB were higher in the Friadent-Schütze PRP (TGF-β1, 196.8 ± 109.6 ng/ml; PDGF-AB, 251.6 ± 115.4 ng/ml) than in the Smart PRePTM (TGF-β1, 77.2 ± 54.8 ng/ml; PDGF-AB, 208 ± 85.2 ng/ml). The sign test indicated significant differences between the two methods in the concentrations of TGF-β1 (P < 0.001) and PDGF-AB (P < 0.01). Insulin-like growth factor (IGF)-1 levels in the two PRP preparations were... [ABSTRACT FROM AUTHOR]

An important reason to improve methods of isolating platelet-rich plasma (PRP) is the potential use of autologous thrombocyte growth factors. In addition to discontinuous cell separation, two methods for extracting PRP that can be performed directly by the surgeon are now available. This study compared the suitability of these two methods for the preparation of PRP. Whole blood was drawn from 47 healthy donors (18 men, 29 women) aged 20–59 years (mean 29.9, SD 7.7). For each donor, PRP was separated by the PCCS method (PCCS Kit, 3i Implant Innovations, Palm Beach Gardens, FL, USA) and by the Curasan method (analogous to the PRP kit, Curasan, Kleinostheim, Germany). Thrombocyte counts differed significantly (sign test P = 0.001) between the donor blood (mean 290,000/µl, SD 86,000/µl), the PCCS PRP preparation (mean 2,209,000/µl, SD 901,000/µl), and the Curasan PRP (mean 1,075,000/µl, SD 636,000/µl). The correlation between the thrombocyte count in the PRP and the thrombocyte count in the donor whole blood was greater for the PCCS PRP (Spearman's correlation coefficient r S = 0.60) than for the Curasan PRP (r S = 0.34). A slight, clinically irrelevant, influence of gender on thrombocyte concentration in whole blood was found, but no influence of age was detected. [ABSTRACT FROM AUTHOR]